Despite continuous bioprocessing being talked about as the future of manufacturing in biologics for years, this has not become reality. However, in recent years, the US government has begun to dedicate funds to intensify the production of biologics.
The need to vaccinate billions of people against COVID-19 as quickly as possible has caused demand for bioprocessing equipment to soar in recent quarters. Now, amid questions about whether demand from the pandemic is peaking, the industry is preparing...
Continuous bioprocessing facilities can be more cost-effective than stainless steel batch plants when total out-of-pocket costs across development and commercial activities are factored in, according to a study.
A new report published by Meticulous Research shows the continuous bioprocessing market is expected to grow at a CAGR of 22.9% from 2020 to 2027 to reach US$197.8m by the end of the period.
Upstream processes were the focus of most early applications of continuous bioprocessing. That is now changing, with many biologic manufacturers evaluating downstream continuous processing and suppliers preparing their portfolios for the anticipated pivot...
Special Edition: The Future of Continuous BioProcessing
The shift away from batch downstream processing has moved closer in recent years amid progress on techniques such as antibody purification using continuous chromatography media. However, there remain barriers to clear before manufacturing facilities that...
A report claims that despite significant interest in implementing continuous bioprocesses, fully continuous systems are five to 10 years away from widespread adoption.
Biosana to work collaboratively with the Bioprocessing Technology Institute, aiming to design a highly flexible and cost-effective continuous manufacturing solution.
The abundance of data made available by continuous bioprocessing allows for more control over the process and can thereby improve the quality of the product, says Pall executive.
At the BIA’s annual conference, industry executives discussed the UK’s position as a leader in bioprocessing and what steps must be taken to keep pace with global innovation.
Sanofi opens its Massachusetts, US-based facility that will use digital technology for continuous biologic production, with similar plants planned in Canada, Brazil, Ireland, France, and Belgium.
